Revenue: As of FY2025 Q3, the actual value is USD 528.56 K.EPS: As of FY2025 Q3, the actual value is USD -0.66.EBIT: As of FY2025 Q3, the actual value is USD -2.355 M.<h3>Segment Revenue</h3><ul><li>Product Revenues: For the three months ended September 30, 2025, product revenues net of discounts and rebates were $437,602, compared to $135,293 for the same period in 2024, representing a 223.45% increase.</li><li>Research Revenues: Research revenues for the three months ended September 30, 2025 were $90,960, compared to $12,818 for the same period in 2024, representing a 609.63% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, the net loss attributed to 60 Degrees Pharmaceuticals, Inc. was $2,316,324, compared to $2,159,785 for the same period in 2024.</li><li>Gross (Loss) Profit: The gross loss for the three months ended September 30, 2025 was $100,088, compared to a gross profit of $23,606 for the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended September 30, 2025 were $2,316,397, compared to $2,155,116 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $5,156,566, compared to $4,009,871 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $1,625,347, compared to net cash used in investing activities of $1,887,016 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $5,979,077, compared to $7,052,598 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Inventory Write-offs: Write-offs of expiring inventory for the three months ended September 30, 2025 were $436,561, compared to $1,165 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to fund operations through third-party and related party debt/advances, private placement of restricted securities, and issuance of stock in subsequent offerings until profitability is achieved.</li><li>Non-Core Business: The company is exploring strategic partnerships and collaborations, such as the partnership with the Icahn School of Medicine at Mount Sinai for a planned Phase II clinical study of tafenoquine in treating chronic babesiosis.</li><li>Priority: The company aims to achieve profitability by raising additional capital to fund activities related to commercial support for its existing product and future clinical research trials.</li></ul>

60 Degrees Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 528.56 K